Latest Breaking News On - Modulator drug candidates - Page 1 : comparemela.com

Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the Second Quarter of 2023Top-Line Results from the Phase 2 Clinical Trial of ADX-629 in Chronic Cough Expected in the Second Quarter of 2023Top-Line Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic.

United statesClin ophthalmolJ clin diagnPtoddc bradyDrug administration new application priorityExchange commissionDrug administrationDrug administration new applicationSecurities exchangeAldeyra therapeutics incTop line resultsRetinitis pigmentosa expectedSecond quarterNline resultsChronic cough expectedAllergic conjunctivitis expected